Molly Reeves
Family · Auburn, ALNPI 1912356858
Payments from drug & device makers
Across 758 payments — averaging $208.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Janssen Scientific Affairs, LLC$37K
- Johnson & Johnson$33K
- Amgen$17K
- UCB, Inc.$1K
- AstraZeneca$975
- plus $5K from 21 others
What the payments were for
- Consulting fees$2,2751%
- Speaking & faculty fees$86,92155%
- Travel & lodging$52,41633%
- Food & beverage$16,47010%
- Education$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 227 | $64,985 |
| Janssen Scientific Affairs, LLC | 46 | $37,061 |
| Johnson & Johnson(2 entities) | 70 | $32,699 |
| Amgen(2 entities) | 114 | $16,712 |
| UCB, Inc. | 56 | $1,001 |
| AstraZeneca(2 entities) | 30 | $975 |
| Mallinckrodt Hospital Products Inc. | 22 | $733 |
| GSK | 34 | $677 |
| Pfizer | 36 | $631 |
| Novartis | 31 | $515 |
| Lilly USA, LLC | 26 | $448 |
| ANI Pharmaceuticals, Inc. | 15 | $440 |
| Sanofi | 1 | $338 |
| Aurinia Pharma U.S., Inc. | 8 | $230 |
| Radius Health, Inc. | 11 | $227 |
| E.r. Squibb & Sons, L.L.C. | 10 | $182 |
| Sobi, Inc | 8 | $147 |
| Tersera Therapeutics LLC | 2 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$68,077
- Rinvoq$53,437
- Tremfya$45,681
- STELARA$36,695
- Enbrel$14,407
- Skyrizi$5,999
- KEVZARA$338
- SAPHNELO$230
- Repatha$125
- PURIFIED CORTROPHIN GEL$103
How this compares
$158,240 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 82 | $556,722 |
| Humira(Cf) PenAdalimumab | 39 | $345,592 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $213,392 |
| Enbrel SureclickEtanercept | 29 | $206,295 |
| OtezlaApremilast | 29 | $138,838 |
| Cosentyx Sensoready PenSecukinumab | 17 | $124,883 |
| Xeljanz XrTofacitinib Citrate | 19 | $107,637 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $93,703 |
| BenlystaBelimumab | 18 | $87,200 |
| Orencia ClickjectAbatacept | 15 | $83,239 |
| OlumiantBaricitinib | 21 | $56,435 |
| ForteoTeriparatide | 12 | $50,273 |
| TymlosAbaloparatide | 16 | $41,459 |
| Hydroxychloroquine Sulfate | 302 | $27,008 |
| RasuvoMethotrexate/Pf | 29 | $16,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $64,985 | $556,72282 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,001 | $213,39222 claims |
| AmgenOtezla | $16,712 | $138,83829 claims |
| Lilly USA, LLCOlumiant, Forteo | $448 | $106,70733 claims |
| GSKBenlysta | $677 | $87,20018 claims |
| Radius Health, Inc.Tymlos | $227 | $41,45916 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $40 | $11,73882 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Auburn
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.